Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/06/2003WO2002064096A3 Methods of using pyrimidine-based antiviral agents
03/06/2003WO2002064092A3 Method for evaluating therapeutic efficacy
03/06/2003WO2002063961B1 Composition and methods for modulation of vascular structure and/or function
03/06/2003WO2002060972A3 Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
03/06/2003WO2002060387A3 Use of prostaglandin analogs for treatment of cardiac conditions
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002058692A9 Halogenated composition, method for preparing same and uses thereof
03/06/2003WO2002058681A8 Use of rhein for preparing a medicine for treating a high level of il-1
03/06/2003WO2002058625A3 Herbal composition for angina pectoris, method to prepare same and uses thereof
03/06/2003WO2002057224A3 Synthesis and antimicrobial activityof novel dicationic 'reversed amidines'
03/06/2003WO2002056867A3 Extended release pharmaceutical compositions containing beta-lactam antibiotics
03/06/2003WO2002056832A3 Methods to treat autoimmune and inflammatory conditions
03/06/2003WO2002055507A8 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
03/06/2003WO2002055106A3 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002051383A3 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
03/06/2003WO2002050093A3 Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
03/06/2003WO2002047689A3 Use of cetirizine or efletirizine for preventing urticaria
03/06/2003WO2002047671A3 Lactam compound to inhibit beta-amyloid peptide release or synthesis
03/06/2003WO2002046160A3 Process for making a thrombin inhibitor
03/06/2003WO2002045742A8 Lipoteichoic acid immunogenic compositions and methods of making and using thereof
03/06/2003WO2002043507A3 Nutrient supplements and methods for treating autism and for preventing the onset of autism
03/06/2003WO2002041837A3 Treatment of mucositis
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002028409A3 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
03/06/2003WO2002028376A3 Chrono delivery formulations and method of use thereof
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002022132A8 Novel topical oestroprogestational compositions with systemic effect
03/06/2003WO2002017870A3 Clear antiperspirants and deodorants made with siloxane-based polyamides
03/06/2003WO2002012325A3 Suppressor gene
03/06/2003WO2002012281A9 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
03/06/2003WO2002009714A9 Compositions and methods for the treatment of anorectal disorders
03/06/2003WO2002009537A3 Alpha- (1, 4) linked glucose polymers containing oral compositions to alleviate or prevent tooth damage
03/06/2003WO2002005797A8 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia
03/06/2003WO2002004423A8 Thrombin inhibitors comprising an aminoisoquinoline group
03/06/2003WO2002003984A3 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
03/06/2003WO2002000650A9 Novel compounds possessing antibacterial, antifungal or antitumor activity
03/06/2003WO2001098343A9 Conserved diaphanous-related formin autoregulatory domain (dad)
03/06/2003WO2001089483A9 Tablets and methods for modified release of hydrophilic and other active agents
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003WO2001068103A9 Treatment of herpes infection using immunomodulatory polynucleotide sequences
03/06/2003WO2001068076A3 D-enantiomer of dfmo and methods of use thereof for treating cancer
03/06/2003WO2001066741A9 Kcnb: a novel potassium channel protein
03/06/2003WO2001063539A3 Anti-infective agents useful against multidrug-resistant strains of bacteria
03/06/2003US20030046718 Administering compounds having an effect on cardiac fibrosis, myocardial infarction, defects in electrical conductance, atherosclerosis, unstable plaque, and stroke in an animal which does not express an active SR-BI, and an apolipoprotein
03/06/2003US20030045865 Compositions and techniques for localized therapy
03/06/2003US20030045830 Inhibiting the expression of a specific gene involved in eye function by inducing or reverting a mutation in that gene by topically applying or injecting the chimeric oligonucleotide
03/06/2003US20030045829 Therapeutic agent delivery tampon
03/06/2003US20030045755 Polyamine analogues as cytotoxic agents
03/06/2003US20030045746 Phosphorous organic compounds and their use
03/06/2003US20030045742 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045726 Novel immunotherapeutic agents
03/06/2003US20030045724 Benzimidazole compound crystal
03/06/2003US20030045721 Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
03/06/2003US20030045720 Mixing the narcotic alkaloid with an acid in the presence of a catalyst in the substantial absence of hydrogen gas
03/06/2003US20030045718 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
03/06/2003US20030045715 Useful in treating and suppressing human Cytomegalovirus
03/06/2003US20030045706 Method for preparing functionalised beta-(1,3)-glucan derivatives
03/06/2003US20030045695 Ribozyme for detecting gene sequence
03/06/2003US20030045690 Having a mean diameter of 200-2000 nm, obtained by solidification from a mixture comprising fibrinogen, thrombin and Factor XIII in an water in oil emulsion
03/06/2003US20030045602 Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
03/06/2003US20030045586 Use of amines
03/06/2003US20030045585 Treatment of psoriasis
03/06/2003US20030045584 Instilling a beta blocker directly into the subject's coronary artery prior to percutaneous coronary intervention; kit containing a catheter and a beta-blocker such as propranolol
03/06/2003US20030045583 Novel succinate salt of O-desmethyl-venlafaxine
03/06/2003US20030045582 Method for treating hyperglycemia
03/06/2003US20030045581 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
03/06/2003US20030045580 Making, by coating ibuprofen or its salt with hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose or gelatin as binder, in specified weight percents; dosage forms
03/06/2003US20030045579 Compounds and compositions for delivering active agents
03/06/2003US20030045578 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
03/06/2003US20030045577 Method for preventing infectious respiratory diseases
03/06/2003US20030045576 Composition for pain mediation and apparatus and method of use thereof
03/06/2003US20030045575 Such as 5-benzylaminosalicylic acid; for treatment of disorders caused by activation of N-methyl-D-aspartate (NMDA) glutamate receptors, entry and accumulation of Zn2+, or free radicals such as Huntington's/Parkinson's/Alzheimer's diseases
03/06/2003US20030045574 Such as alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dimethyladamantane)nitrone for treatment of neurological/ inflammatory diorders, and aging, which result from the overproduction of nitric oxide
03/06/2003US20030045572 Anti-inflammation analgesic preparation
03/06/2003US20030045571 Process and intermediates to prepare latanoprost
03/06/2003US20030045570 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
03/06/2003US20030045569 Difluoromethylene aromatic ethers as inhibitors of glycine transport
03/06/2003US20030045568 Treating hepatitis C viral infections with thiosemicarbazone compounds
03/06/2003US20030045567 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003US20030045566 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045564 Saururus chinensis extract for prevention and treatment of neurodegenerative disease
03/06/2003US20030045563 Comprises cyclooxygenase-2 inhibitors (celecoxib, rofecoxib); water solubility; vasodilation/headache relief; for inhibition of precipitation and/or crystallization in gastrointestinal fluids
03/06/2003US20030045562 Administering in combination, a cyclooxygenase-2 inhibitor, low dose aspirin, and antioxidant flavonoids/isoflavones
03/06/2003US20030045561 With use of eprosartan as nonpeptide receptor antagonist in renin-angiotensin system, controlling blood pressure
03/06/2003US20030045560 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
03/06/2003US20030045559 Such as 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one for treatment of inflammatory joint and skin diseases, and dysproliferative diseases such as cancer; wound healing agents
03/06/2003US20030045558 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
03/06/2003US20030045557 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045553 Peroxisome proliferator-activated receptor agonists (PPAR) for increasing insulin sensitivity in treatment of diabetes and Syndrome X
03/06/2003US20030045552 Isoindole-imide compounds, compositions, and uses thereof
03/06/2003US20030045551 Pseudopolymorph of ( - ) -cis -2-(2 -chlorophenyl) -5, 7-dihydroxy-8 [4R- ( 3S-hydroxy -1-methyl)piperidinyl ] -4H -1 -benzopyran-4-one
03/06/2003US20030045550 Bicyclic aromatic chemokine receptor ligands
03/06/2003US20030045547 Reacting a 5-hydroxy carbostryil derivative with a tetrazole in the presence of a phase transfer catalyst
03/06/2003US20030045546 Anticancer agents
03/06/2003US20030045545 Immunomodulators, induce cytokine biosynthesis, and antineoplastic agents
1 ... 5543 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 5556 5557 5558 5559 5560 5561 5562 5563 ... 7860